Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2026-03-26 Remuneration Information
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
董事会薪酬与考核委员会关于公司2025年限制性股票激励计划首次授予激励对象名单的核查意见及公示情况说明
Remuneration Information Classification · 95% confidence The document is an official announcement from the Board Remuneration and Assessment Committee regarding the verification and public disclosure of the initial grant list of restricted stock incentive plan for 2025. It details the internal verification process, public notice, and compliance with relevant laws and regulations. The content focuses on remuneration and incentive plan details, specifically about stock incentives and the eligibility of recipients. It is not a full annual report, audit report, or financial statement. It is not a proxy solicitation or voting result announcement. The document is primarily about remuneration and incentive plan disclosures, which aligns with Remuneration Information filings.
2026-03-26 Chinese
2026年第一次临时股东会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2026 First Extraordinary General Meeting (EGM) Meeting Materials" for Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It contains detailed meeting instructions, agenda, and multiple proposals related to the 2025 restricted stock incentive plan. The content is focused on the materials prepared for the shareholders to review and vote on during the EGM. There are no financial statements or earnings data presented, nor is this a transcript or announcement of voting results. The document is clearly the meeting materials provided for the shareholders to consider at the EGM, which fits the definition of AGM Information (AGM-R), as it is the presentation and materials shared during a shareholders meeting (in this case, an extraordinary general meeting). The document length is sufficient and contains substantive content, not just an announcement or notice. Therefore, the correct classification is AGM Information (AGM-R).
2026-03-26 Chinese
自愿披露关于宣泰?番茄红葡萄籽提取物片获得国产保健食品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a registration certificate for a health food product. It includes product details, regulatory approval information, and a risk warning to investors. There is no financial data, no mention of financial results, no meeting materials, no voting results, no management changes, no legal proceedings, and no report publication. The document is a regulatory announcement about product registration and its impact on the company, which fits best under Regulatory Filings (RNS). The document length is short and it is not a report itself but an announcement of a regulatory approval.
2026-03-17 Chinese
关于召开2026年第一次临时股东会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2026 first extraordinary general meeting (临时股东会) of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and instructions for shareholders. It does not contain financial statements or results but is an announcement related to a shareholders' meeting. The document length is 3406 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2026-03-16 Chinese
自愿披露关于合作产品恩扎卢胺片获得国家药品监督管理局批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the approval of a cooperative product, Enzalutamide tablets, by the National Medical Products Administration (NMPA) of China. It details the drug's registration, approval number, indications, and impact on the company. The document is an official announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is short (1176 characters) and it serves as a formal disclosure of a regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-13 Chinese
关于2025年限制性股票激励计划（草案修订稿）获得上海市国有资产监督管理委员会批复的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the approval by the Shanghai State-owned Assets Supervision and Administration Commission of the company's 2025 restricted stock incentive plan draft revision. It mentions board meetings and the need for shareholder approval. The content focuses on the stock incentive plan approval process and regulatory compliance, not on financial results, audit, or detailed reports. The document length is short (777 characters) and it is an announcement of an approval and next steps rather than a full report or detailed financial disclosure. This fits best with a Capital/Financing Update (CAP) as it relates to stock incentive plans and equity-related corporate actions.
2026-03-10 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.